• About
    • Company Overview
    • Management Team
    • Board of Directors
    • Science Advisors
    • Neurology Advisors
    • Ophthalmology Advisors
    • Contacts
  • Science
    • Publications
    • Collaborators
  • Pipeline
    • Infantile Neuroaxonal Dystrophy (INAD)
    • Friedreich’s Ataxia (FA)
    • Amyotrophic Lateral Sclerosis (ALS)
    • Progressive Supranuclear Palsy (PSP)
    • Dry AMD
    • Future Targets
  • Patient Resources
    • Expanded Access Policy
    • Clinical Trials
    • Additional Resources
  • News & Events
    • Press Releases
    • News
    • Events
    • Videos
  • Careers
HomeManagementMikhail S. Shchepinov, PhD

Mikhail S. Shchepinov, PhD

Founder, Chief Scientific Officer and Director

Mikhail S. Shchepinov, Ph.D. is a founder of Retrotope and also serves as the company’s chief scientific officer.  In this role, he oversees the company’s efforts to employ stable isotopes to reinforce biomolecules against disease of oxidative stress and aging.  Prior to Retrotope, Dr. Shchepinov held positions at biotechnology companies in both the U.S. and Europe, making key contributions to their development of novel chemical tools for genomics and proteomics.  These included San Diego-based Sequenom and Tridend Technologies in Oxford, UK.

Dr. Shchepinov completed his postdoc studies at Oxford University with a focus on bioorganic, combinatorial and surface chemistries.  He also completed his Ph.D. at Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry in Moscow (1994) and his master’s degree from Mendeleev Institute of Chemical Technology in Moscow, USSR.

About
Science
  • Publications
Pipeline
  • Clinical
  • Preclinical
  • Future Targets
Patient Resources
  • Expanded Access Policy
News & Events
Careers
RETROTOPE, 4300 EL CAMINO REAL, SUITE 201, LOS ALTOS, CA 94022
Copyright ©️ 2015-2021 Retrotope Inc.
You are leaving Retrotope’s website. Retrotope does not guarantee the accuracy or completeness of the information contained on any third-party sites, nor does it endorse any of the opinions or information contained on those sites. Please click CONFIRM to continue. CONFIRM